Patents Issued in February 18, 2014
  • Patent number: 8653257
    Abstract: Compounds the following formula: wherein Z is as described in the specification, pharmaceutically acceptable salts thereof, compositions comprising the same, and methods of treating bipolar disorder, an anxiety disorder, a mood disorder or schizophrenia or other psychotic disorder with said compounds.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: February 18, 2014
    Assignee: Astrazeneca AB
    Inventors: Dean Brown, James R. Damewood, Phil Edwards, James Hulsizer, James Campbell Muir, M. Edward Pierson, Jr., Ashokkumar Bhikkappa Shenvi, Steven Wesolowski, Dan Widzowski, Michael Wood
  • Patent number: 8653258
    Abstract: The present disclosure encompasses compounds and compositions that are useful as specific AI-2 antagonists for the control of bacterial quorum sensing. Although the AI-2 antagonists according to the present disclosure may not have bactericidal effect, their ability to attenuate virulence, drug resistance, and/or biofilm formation have therapeutic benefits. In addition, the AI-2 antagonists of the present disclosure can also be used as tools to probe bacterial AI-2 functions. The present disclosure also encompasses methods for inhibiting or attenuating microbial virulence, biofilm formation, and drug resistance. The methods are suitable for preventing bacteria from accruing and forming extensive biofilms that may be a health or hygiene hazard or a physical issue, such as in the blockage of water or fuel lines.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: February 18, 2014
    Assignee: Georgia State University Research Foundation, Inc.
    Inventors: Binghe Wang, Nanting Ni, Junfeng Wang, Chung-Dar Lu, Han-Ting Chou, Minyong Li, Shilong Zheng, Yunfeng Cheng, Hanjing Peng
  • Patent number: 8653259
    Abstract: The invention provides the process illustrated in scheme 1 for synthesizing heterocyclic compounds of formula I. In the process, an isothiocyanate of formula II is initially reacted with a primary amine or formula III to give a thiourea of formula IV. Subsequently, the thiourea of formula IV is converted to the corresponding heterocycle of formula I using a base and a sulfonyl chloride.
    Type: Grant
    Filed: February 6, 2008
    Date of Patent: February 18, 2014
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Uwe Heinelt, Hans-Jochen Lang
  • Patent number: 8653260
    Abstract: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of ?3-adrenoceptor.
    Type: Grant
    Filed: June 20, 2012
    Date of Patent: February 18, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Richard Berger, Lehua Chang, Scott D. Edmondson, Stephen D. Goble, Sookhee Nicole Ha, Nam Fung Kar, Ihor E. Kopka, Bing Li, Gregori J. Morriello, Chris R. Moyes, Ding-Ming Shen, Liping Wang, Cheng Zhu
  • Patent number: 8653261
    Abstract: Actinomysin-based near IR emitting compounds and methods of their use as nucleic acid stains are provided. The actinomysin-based near IR emitting compounds have the structure: wherein R is H or NH2; R1, R2, R3, and R4 are independently a moiety comprising 1-30 atoms selected from H, O, C, and N, wherein the atoms are in a linear, branched, or cyclic configuration; R3 and/or R4 comprise a quaternary nitrogen atom; and R5 is H, F, or Cl.
    Type: Grant
    Filed: October 26, 2009
    Date of Patent: February 18, 2014
    Assignee: Life Technologies Corporation
    Inventors: Stephen Yue, Jixiang Liu, Jolene Bradford
  • Patent number: 8653262
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Grant
    Filed: May 29, 2008
    Date of Patent: February 18, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Heiner Ebel, Silke Hobbie
  • Patent number: 8653263
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Grant
    Filed: October 21, 2010
    Date of Patent: February 18, 2014
    Assignee: Janssen Pharmaceutica
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode-Johnson, Emily M. Stocking, Devin M. Swanson
  • Patent number: 8653264
    Abstract: A novel crystal of antitumor drug erlotinib base and its preparation method are provided in the present invention. A preparation method of erlotinib hydrochloride with high-purity is also provided in the present invention.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: February 18, 2014
    Assignee: Zhejiang Huahai Pharmaceutical Co., Ltd.
    Inventors: Ke Xiang, Min Xu
  • Patent number: 8653265
    Abstract: A preparation method of rosuvastatin calcium (Formula 1), which can be used for the production of medicament lowering the levels of LDL-cholesterol and triglycerides in vivo, is provided. Such preparation method is suitable for industrial production. Furthermore, the intermediate crystallines used in the preparation method are provided.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: February 18, 2014
    Assignee: Changzhou Pharmaceutical Factory
    Inventors: Benshun Chen, Bing Wang, Xiaofeng Jin, Lin Zou
  • Patent number: 8653266
    Abstract: A novel process for the preparation of Etravirine comprises the condensing of ethyl cyanoacetate with N-cyanophenylguanidine to obtain an —OH compound of formula (II), which is further converted to a leaving group of formula (III). The compound of formula (III) is optionally protected and brominated to yield compound of formula (IV). The condensation of formula (IV) with 3,5-dimethyl-4-hydroxybenzonitrile yields a compound of formula (VI), and an optional deprotection of the compound of formula (VI) results in Etravirine.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: February 18, 2014
    Assignee: Mylan Laboratories Limited
    Inventors: Vinayak Gore, Choudhari Bharati, Mahesh Hublikar, Prakash Bansode, Sandip Sinore
  • Patent number: 8653267
    Abstract: The present invention discloses a co-crystal compound of optical devices. The co-crystal compound is crystallized out with hydrogen bonding by a temperature fluctuation method after mixing small organic molecules without optoelectronic properties and organic molecules having heterocyclic rings with optoelectronic properties. The photoluminescence (PL) intensity of this hydrogen-bonded co-crystal compound according to the present invention can vary with a variety of the small organic molecules without optoelectronic properties, so as to modulate the PL intensity.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: February 18, 2014
    Assignee: National Central University
    Inventors: Tu Lee, Pu-Yun Wang
  • Patent number: 8653268
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: February 18, 2014
    Assignee: OSI Pharmaceuticals, LLC
    Inventors: Mark J. Mulvihill, Radoslaw Laufer, An-Hu Li, Arno G. Steinig
  • Patent number: 8653269
    Abstract: Provided is a process for the preparation of t-butoxycarbonylamine compounds, which comprises using phosgene or a phosgene equivalent, t-butanol, and an organic base. Even when applied to a primary or secondary amine compound having low nucleophilicity, the process enables highly selective preparation of a t-butoxycarbonylamine compound at a low cost. In the process, a t-butoxycarbonylamine compound is prepared using: phosgene or a phosgene equivalent; t-butanol; an organic base; and either a primary or secondary amine compound or a primary or secondary ammonium salt.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: February 18, 2014
    Assignee: Nippon Soda Co., Ltd.
    Inventors: Hiroki Inoue, Kaoru Noda
  • Patent number: 8653270
    Abstract: The present invention relates to novel derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: February 18, 2014
    Assignee: Allergan, Inc.
    Inventors: Todd M. Heidelbaugh, Phong X. Nguyen
  • Patent number: 8653271
    Abstract: The present invention is directed to novel codrugs comprising bupropion or hydroxybupropion and an opioid antagonist or an opioid agonist joined together by chemical bonding. The codrugs provide a significant increase in the transdermal flux across human skin, as compared to the basic opioid antagonist or opioid agonist.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: February 18, 2014
    Assignee: University of Kentucky Research Foundation
    Inventors: Audra L. Stinchcomb, Peter A. Crooks, Mohamed O. Hamad, Paul K. Kiptoo
  • Patent number: 8653272
    Abstract: A series of heteroaryl-substituted fused pyridine derivatives, in particular heteroaryl-substituted thieno[3,2-6]pyridine derivatives, being selective inhibitors of PO kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: February 18, 2014
    Assignee: UCB Pharma S.A.
    Inventors: Kerry Jenkins, Christopher James Lock, Andrew James Ratcliffe
  • Patent number: 8653273
    Abstract: The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: February 18, 2014
    Assignee: The Trustees of Columbia University in the city of New York
    Inventors: Kirsten Alison Rinderspacher, Donald W. Landry, Yuli Xie, Yidong Liu, Gangli Gong, Shi-Xian Deng
  • Patent number: 8653274
    Abstract: The present invention relates to novel derivatives that are suitable as precursors to compounds that are useful for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. The compounds deriving from these precursors are useful in methods of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease by positron emission tomography (PET) as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents. Furthermore, the present invention also discloses the precursor compounds in crystalline form.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: February 18, 2014
    Assignee: AstraZeneca AB
    Inventors: Seth Bjork, Vern Delisser, Peter Johnstrom, Nils Anders Nilsson, Katinka Ruda, Per Magnus Schou, Britt-Marie Swahn
  • Patent number: 8653275
    Abstract: Provided are bis-quaternary ammonium cyclophane compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and or gastrointestinal tract disorders.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: February 18, 2014
    Assignee: University of Kentucky Research Foundation
    Inventors: Peter Crooks, Linda P. Dwoskin, Guangrong Zheng, Sangeetha Sumithran, Davis D. Allen, Zhenfa Zheng, Paul Lockman
  • Patent number: 8653276
    Abstract: The present invention is directed to compounds of the general formula: as defined herein, and pharmaceutical compositions thereof. The invention is also directed to their therapeutic use as urotensin II receptor antagonists, e.g., in the treatment of cardiac, coronary, and central nervous system disorders. In particular embodiments, the invention relates to 5,6-bisaryl-2-pyridinecarboxamides, to their preparation and to their therapeutic use as urotensin II receptor antagonists.
    Type: Grant
    Filed: May 15, 2013
    Date of Patent: February 18, 2014
    Assignee: SANOFI
    Inventors: Jean-Michel Altenburger, Valerie Fossey, Daniel Galtier, Frederic Petit
  • Patent number: 8653277
    Abstract: It is to provide a fungicidal composition having stable and high fungicidal effects against cultivated crops infected with plant diseases resulting from plant diseases.
    Type: Grant
    Filed: May 29, 2009
    Date of Patent: February 18, 2014
    Assignee: Ishihara Sangyo Kaisha, Ltd.
    Inventors: Hisaya Nishide, Shigeyuki Nishimura, Shigeru Mitani, Koji Minamida, Fumio Kanamori, Munekazu Ogawa, Shigehisa Kanbayashi, Toyoshi Tanimura, Koji Higuchi, Hidemasa Kominami, Tomohiro Okamoto, Akihiro Nishimura
  • Patent number: 8653278
    Abstract: One aspect of the invention relates to isoform-selective HDAC inhibitors. Also provided are methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy. The invention also provides methods for treating cancer, methods for treating neurological diseases and methods for treating malaria. Additionally, the invention provides pharmaceutical compositions comprising an HDAC inhibitor of the invention; and kits comprising an HDAC inhibitor of the invention.
    Type: Grant
    Filed: August 2, 2007
    Date of Patent: February 18, 2014
    Assignees: Georgetown University, The Board of Trustees of the University of Illinois
    Inventors: Alan P. Kozikowski, Mira Jung, Anatoly Dritschilo, Arsen Gaysin, Pavel A. Petukhov, Werner Tueckmantel, Hongbin Yuan, Yufeng Chen
  • Patent number: 8653279
    Abstract: The present embodiments relate to a dye for a dye-sensitized solar cell and a dye-sensitized solar cell prepared from the same. The dye includes a fluorenyl-containing compound. The dye according to the present embodiments is applied to a light absorption layer to improve photovoltaic efficiency and increase an open-circuit voltage.
    Type: Grant
    Filed: April 16, 2007
    Date of Patent: February 18, 2014
    Assignee: Samsung SDI Co., Ltd.
    Inventors: Jae-Kwan Lee, Ji-Won Lee, Jae-Jung Ko, Sang-Hoon Kim, Soo-Jin Moon, Moon-Sung Kang, Moon-Seok Kwon
  • Patent number: 8653280
    Abstract: The present invention is directed to novel compounds of formula (I) as well as to the process for their preparation. Novel compounds of formula (I) can be converted into asenapine through an efficient process. The invention also relates to novel intermediates used in this process and their use in the preparation of compounds of formula (I).
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: February 18, 2014
    Assignee: Laboratories Lesvi, S.L.
    Inventors: Pere Dalmases Barjoan, Juan Huguet Clotet, Jordi Peirats Masia
  • Patent number: 8653281
    Abstract: A process for the manufacture of agomelatine and its intermediate N-[2-(7-methoxy- 1-naphthy)ethyl]phthalimide is provided and inclues reacting 7-methoxy-1-naphthyl ethanol (III) with benzenesulfonyl chloride to obtain 7-methoxy-1 -naphthylethyl benzene sulfonate (IV), which is reacted with potassium phthalimide to produce N-[2-(7-methoxy-1-naphthy)ethyl]phthalimide (II); and subjecting N-[2-(7-methoxy-1-naphthy)ethyl]phthalimide (II) to alkaline hydrolysis and acetylation, to obtain agomelatine.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: February 18, 2014
    Assignee: NHWA Pharma. Corporation
    Inventors: Guisen Zhang, Daopeng Chen, Yanqin Ma, Xiangping Yang, Shixia Zhou, Liang Chen
  • Patent number: 8653282
    Abstract: The invention relates to improved methods of preparing dihydrothienopyrimidines of formula 1, and intermediates thereof, (I) wherein X is SO or SO2, preferably SO, and wherein RA, R1, R2, R3, R4 and R5 have the meanings given in the description. The methods according to this invention are more suitable for large-scale synthesis of said compounds than prior methods because the new synthetic process avoids distillation and chromatographic purification between steps and results in a higher overall yield of the desired product.
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: February 18, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rogelio Frutos, Dhileepkumar Krishnamurthy, Jason Alan Mulder, Sonia Rodriguez, Chris Hugh Senanayake, Thomas G. Tampone
  • Patent number: 8653283
    Abstract: The present disclosure relates generally to compositions and methods for treating cancer. In some aspects, novel spirohexenolides and methods of using and producing them are described.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: February 18, 2014
    Assignee: The Regents of The University of California
    Inventors: Michael D. Burkart, James J. La Clair, MinJin Kang, Brian D. Jones, Alexander L. Mandel, Wei-Luen Yu, Justin C. Hammons
  • Patent number: 8653284
    Abstract: This invention provides a novel class of compounds and compositions and synthetic methods related to lactone antioxidant 3-arylbenzofuranones. The compounds may be useful to prevent yellowing and deterioration of organic materials preferably polymers, such as polyurethane foams as one example. The lactone antioxidants may be polymeric, and may also be liquid or paste in physical form at room temperature. Although it is not necessary for its stabilizing properties, the compositions may, in some species, bear one or more reactive primary OH groups on the polymer chains. The chains may also contain oligomeric oxyalkylene ether and aliphatic ester functional groups, in one embodiment of the invention.
    Type: Grant
    Filed: September 18, 2009
    Date of Patent: February 18, 2014
    Assignee: Milliken & Company
    Inventor: Jusong Xia
  • Patent number: 8653285
    Abstract: An aminopropylidene derivative having excellent histamine receptor antagonistic action, a compound which is useful as a pharmaceutical composition, especially as an active ingredient, having alleviated side effects in the central nervous system is described. In the aminopropylidene derivative, R1 and R2, which may be identical or different, stand for a hydrogen, a substituted carbonyl, a substituted carbonylalkyl, and acrylic acid, excluding a case where both are hydrogen; R3 and R4, which may be identical or different, stand for hydrogen, an alkyl which may be substituted with phenyl, or the like; A stands for unsubstituted or an oxo; B stands for a carbon or an oxygen; one of X and Y stands for a carbon and the other stands for a sulfur, a broken line part stands for a single bond or a double bond, and a wavy line stands for cis-form and/or trans-form.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: February 18, 2014
    Assignee: Nippon Zoki Pharmaceutical Co., Ltd.
    Inventors: Kunihiko Higashiura, Takashi Ogino, Taizo Ito, Koji Kunimasu, Kazuhito Furukawa
  • Patent number: 8653286
    Abstract: Methods for forming maleimide functionalized polymers are provided. In one such embodiment, a maleimide functionalized polymer is prepared in a method that includes a step of carrying out a reverse Diels-Alder reaction. Intermediates useful in the methods, as well as methods for preparing the intermediates, are also provided. Also provided are polymeric reagents, methods of using polymeric reagents, compounds and conjugates.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: February 18, 2014
    Assignee: Nektar Therapeutics
    Inventors: Samuel P. McManus, Antoni Kozlowski, Tracy L. Hutchison, Brian Bray, Xiaoming Shen
  • Patent number: 8653287
    Abstract: A process is provided for the synthesis of furan and related compounds by liquid-phase decarbonylation of furfural and derivatives, using a palladium/metal aluminate catalyst. The compounds so produced can be used as starting materials for industrial chemicals for use as pharmaceuticals, herbicides, stabilizers, and polymers such as polyether ester elastomers and polyurethane elastomers.
    Type: Grant
    Filed: August 31, 2010
    Date of Patent: February 18, 2014
    Assignee: E I du Pont de Nemours and Company
    Inventors: Ronnie Ozer, Ke Li
  • Patent number: 8653288
    Abstract: A process for making a deodorized edible oil or fat having a low level of bound MCPD (monochloro propanediol esters) and/or low level of bound 3-MCPD is described. The process comprises a step of contacting the oil or fat to a carboxymethyl cellulose or an ion exchange resin. The carboxymethyl cellulose can be a Blanose® cellulose gum and the resin can be a cationic resin. A deodorized vegetable oil or fat and a food product made there from is described. The food product can be an infant formula. It exhibits low levels of bound MCPD and/or low level of bound 3-MCPD. In one embodiment the oil or fat has a reduced level of free fatty acid as well as a limpid aspect and no off-flavors.
    Type: Grant
    Filed: July 19, 2010
    Date of Patent: February 18, 2014
    Assignee: Nestec S.A.
    Inventors: Constantin Bertoli, Francois Cauville, Annemarie Johanna Hendrika Schoonman
  • Patent number: 8653289
    Abstract: The present disclosure relates to specific (poly-)glycerol partial esters with at least one carboxylic acid and one polyfunctional carboxylic acid, and to the use thereof as emulsifier and to formulations comprising partial esters of the present disclosure.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: February 18, 2014
    Assignee: Evonik Goldschmidt GmbH
    Inventors: Hans Henning Wenk, Juergen Meyer, Stefan Bergfried, Hannelore Foetsch
  • Patent number: 8653290
    Abstract: Disclosed are a metallocene complex represented by the general formula (I), (II) or (III), and a polymerization catalyst composition containing such a metallocene complex. In the formulae (I), (II) and (III), M represents a lanthanoid element, scandium or yttrium; CpR independently represents an unsubstituted or substituted indenyl; CpR? represents an unsubstituted or substituted cyclopentadienyl, indenyl or fluorenyl; Ra-Rf independently represents a hydrogen or an alkyl group having 1-3 carbon atoms; X and X? respectively represent a hydrogen atom, a halogen atom, an alkoxide group, a thiolate group, an amide group, a silyl group or a hydrocarbon group having 1-20 carbon atoms; L represents a neutral Lewis base; w represents an integer of 0-3; and [B]? represents a non-coordinating anion.
    Type: Grant
    Filed: May 2, 2007
    Date of Patent: February 18, 2014
    Assignees: Riken, Bridgestone Corporation, JSR Corporation
    Inventors: Shojiro Kaita, Olivier Tardif
  • Patent number: 8653291
    Abstract: The invention relates to the use of disubstituted alkynes for the functionalisation of the surface of a substrate consisting of a semi-conductor material, with molecules of interest. According to the invention, a compound of formula A-(E1)n1-F1 is used, wherein A is a linear or cyclic disubstituted alkyne, E1 is an alkyl chain and n2 is 0 or 1, and F1 is a reactive group that can react with the reactive group F2 of a compound of formula F2-(E2)n2-X wherein E2 is an alkyl chain and X is a group having properties of interest. The invention is especially applicable to the field of molecular biology or biotechnology.
    Type: Grant
    Filed: March 16, 2010
    Date of Patent: February 18, 2014
    Assignee: Commissariat a l'Energie Atomique et aux Energies Alternatives
    Inventors: Guillaume Delapierre, Regis Barattin, Aude Bernardin, Isabelle Texier-Nogues
  • Patent number: 8653292
    Abstract: The invention provides novel Zr MOFs, in particular compounds having a surface area of at least 1020 m2/g or if functionalized, having a surface area of at least 500 m2/g.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: February 18, 2014
    Assignee: Universitetet I Oslo
    Inventors: Jasmina Hafizovic, Unni Olsbye, Karl Petter Lillerud, Søren Jakobsen, Nathalie Guillou
  • Patent number: 8653293
    Abstract: A compound having the formula: Each R1 is C1-C3 alkyl group or fluoridated C1-C3 alkyl group. The value n is a positive integer. Each R2 is alkylene group or polyethylene glycol group. Y1 is hydrogen, quaternary ammonium containing group, or phenol-containing group. Y2 is quaternary ammonium-containing group or phenol-containing group. The quaternary ammonium-containing group is non-aromatic and contains no more than one quaternary ammonium.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: February 18, 2014
    Assignee: The United States of America, as represented by the Secretary of the Navy
    Inventors: James H Wynne, Ramesh R. Pant
  • Patent number: 8653294
    Abstract: Novel silicone compounds containing a siloxane moiety and at least one terpenyl moiety, such as limonenyl or valencenyl, and methods for their synthesis, are provided. The novel compounds are appropriate for incorporation into cosmetic formulations due to their low aroma, resistance to deterioration, and favorable solubility properties.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: February 18, 2014
    Assignee: Gelest Technologies, Inc.
    Inventors: Barry C. Arkles, Rudolph Cameron, Youlin Pan, Gerald L. Larson
  • Patent number: 8653295
    Abstract: An ?-trifluoromethyl-?,?-unsaturated ester can be produced by reacting an ?-trifluoromethyl-?-hydroxy ester with sulfuryl fluoride (SO2F2) in the presence of an organic base. It is preferable that the raw substrate has a hydrogen atom as one ?-position substituent group and either an alkyl group, a substituted alkyl group, an alkenyl group, a substituted alkenyl group, an aromatic ring group or a substituted aromatic ring group as the other ?-position substituent group. It is more preferable that an ester moiety of the raw substrate is an alkyl ester. This raw substrate is readily available. Further, the desired reaction can proceed favorably with the use of this raw substrate. It is also preferable to use either 1,5-diazabicyclo[4.3.0]non-5-ene (DBN) or 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) as the organic base. The desired reaction can proceed more favorably with the use of this organic base.
    Type: Grant
    Filed: September 24, 2009
    Date of Patent: February 18, 2014
    Assignee: Central Glass Company, Limited
    Inventors: Akihiro Ishii, Manabu Yasumoto, Takako Yamazaki, Kaori Mogi, Kazunori Mori, Takashi Masuda
  • Patent number: 8653296
    Abstract: A method for preparing esters of cyclohexane polycarboxylic acids from esters of benzene polycarboxylic acids makes improvement to hydrogenation of esters of benzene polycarboxylic acids by using a reaction tank having a gas-introducing mixer capable of extracting and exhausting air and stirring to hydrogenate an ester of a benzene polycarboxylic acids into an ester of a cyclohexane polycarboxylic acid in the presence of a hydrogenation catalyst; resulted in that the method advantageously minimizes the operational pressure for hydrogenating esters of benzene polycarboxylic acids and significantly lowers the reaction temperature for hydrogenation while effectively improving the yield of esters of cyclohexane polycarboxylic acids made from the esters of the benzene polycarboxylic acids.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: February 18, 2014
    Assignee: Nan Ya Plastics Corporation
    Inventors: Dein-Run Fung, Jung-Jen Chuang, Chung-Yu Chen, Heng-Hua Hsiao
  • Patent number: 8653297
    Abstract: A solid acid having a core of calixarene or calix resorcinarene. The solid acid is an ion conducting compound in which at least one of the hydroxyl groups is substituted by an organic group having a cation exchange group at a terminal end, a polymer electrolyte membrane including the same, and a fuel cell using the polymer electrolyte membrane. The polymer electrolyte membrane can provide low methanol crossover and high ionic conductivity. Accordingly, a fuel cell having high efficiency can be obtained by using the polymer electrolyte membrane.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: February 18, 2014
    Assignee: Samsung SDI Co., Ltd.
    Inventors: Jae-jun Lee, Myung-sup Jung, Do-yun Kim, Jin-gyu Lee, Sang-kook Mah
  • Patent number: 8653298
    Abstract: The biphenyl acetate is biphenyl acetic ammonia butantriol salt, which is obtained by reacting biphenyl acetic acid with ammonia butantriol in organic solvent. The salt is adapted to be used for producing analgesic, anti-inflammatory and antithermic medicines.
    Type: Grant
    Filed: September 27, 2007
    Date of Patent: February 18, 2014
    Assignee: Shijiazhuang Yiling Pharmaceutical Co., Ltd.
    Inventors: Wei Wang, Wenzhan Chen
  • Patent number: 8653299
    Abstract: The present invention relates to novel dihydronaphthalene and naphthalene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: February 18, 2014
    Assignee: Allergan, Inc.
    Inventors: Vidyasagar Vuligonda, Richard L. Beard, Thong Vu, John E. Donello, Veena Viswanath, Michael E. Garst
  • Patent number: 8653300
    Abstract: A method for making a hindered phenolic antioxidant based on Octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate uses a methanol solution containing alkali metal methoxide as a catalyst solution, wherein the catalyst solution is filtered with a filter device with a filter pore diameter of less than 50 ?m to remove insoluble matters therefrom before used in a transesterification process where methyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate and 1-Octadecanol are taken as reactants to obtain a crude product of Octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate having high conversion rate and low color, and the crude product further undergoes a purification process for crystallization, filtering and drying to obtain a product of Octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate having high purity and low color.
    Type: Grant
    Filed: August 3, 2009
    Date of Patent: February 18, 2014
    Assignee: Nan Ya Plastics Corporation
    Inventors: Dein-Run Fung, Jung-Jen Chuang, Zhang-Jian Huang, Chung-Yu Chen
  • Patent number: 8653301
    Abstract: A novel tricyclodecane monomethanol monocarboxylic acid and derivatives thereof, which can be raw materials for highly heat-resistant alicyclic polyesters, are provided. A tricyclodecane monomethanol monocarboxylic acid represented by the following formula (I) and derivatives thereof.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: February 18, 2014
    Assignees: Hitachi Chemical Company, Ltd., National Institute of Advanced Industrial Science and Technology
    Inventor: Hiroyuki Kawakami
  • Patent number: 8653302
    Abstract: Novel processes for preparing poly(pentafluorosulfanyl)aromatic compounds are disclosed. Processes include reacting an aryl sulfur compound with a halogen and a fluoro salt to form a poly(halotetrafluorosulfanyl)aromatic compound. The poly(halotetrafluorosulfanyl)aromatic compound is reacted with a fluoride source to form a target poly(pentafluorosulfanyl)aromatic compound.
    Type: Grant
    Filed: September 21, 2009
    Date of Patent: February 18, 2014
    Assignee: UBE Industries, Ltd.
    Inventor: Teruo Umemoto
  • Patent number: 8653303
    Abstract: In one embodiment, the invention is to a process for producing acetic anhydride. The process includes at least a step of carbonylating methanol and/or a methanol derivative with carbon monoxide to form acetic acid, and contacting ketene with the acetic acid to form a crude acetic anhydride product stream and a vent stream having unreacted ketene. The process further comprises a step of directing at least a portion of the vent stream to a liquid ring vacuum compressor having a ring seal fluid comprising acetic acid The unreacted ketene in the portion of the vent stream contacts the ring seal fluid to form supplemental acetic anhydride.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: February 18, 2014
    Assignee: Celanese International Corporation
    Inventors: R. Jay Warner, Melchoir Meilchen
  • Patent number: 8653304
    Abstract: A 2,3-dihydro-1H-indene-2-yl urea represented by Formula (Ia) or a pharmaceutically acceptable salt thereof:
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: February 18, 2014
    Assignee: Toray Industries, Inc.
    Inventors: Hiroaki Kaneko, Hideki Kawai, Yosuke Iura, Hideki Inoue, Mie Kaino, Hiroyuki Meguro, Tazuru Uchida
  • Patent number: 8653305
    Abstract: Provided are: a compound represented by formula (I): (wherein ring A and ring D each represent a cyclic group which may have a substituent(s); E and G each represent a bond or a spacer having 1 to 8 atoms in its main chain; L represents a hydrogen atom or a substituent; X represents amino which may have a substituent(s), or a heterocylcic group which contains at least one nitrogen atom and which may have a substituent(s); n represents 0 to 3, and when n is 2 or more, a plurality of ring A's may be the same or different from one another); a salt, an N-oxide form, a solvate, or a prodrug thereof; and a medicament which includes those. The compound of formula (I) is capable of binding S1P receptors (in particular, EDG-1 and/or EDG-6), and useful for preventing and/or treating rejection in transplantation, autoimmune diseases, allergic diseases, etc.
    Type: Grant
    Filed: September 7, 2011
    Date of Patent: February 18, 2014
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Hiromu Habashita, Shinji Nakade
  • Patent number: 8653306
    Abstract: An improved method for the production of 2-amino-1,3-propanediol (serinol) and its bis-adduct, 2,2?-iminobis-1,3-propanediol, from dihydroxyacetone and ammonia in the presence of a hydrogenation catalyst such as Raney nickel, followed by separation using an acidic ion-exchange resin.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: February 18, 2014
    Assignee: Penn A Kem LLC
    Inventors: Shridhar G. Hegde, Lei Zhao